Wockhardt, an Indian drug major has signed an agreement with Dubai-based Enso Healthcare and a subsidiary of the Russian Direct Investment Fund (RDIF), for the production and supply of COVID-19 vaccine Sputnik.

The drugmaker has agreed with Enso and Human Vaccine LLC, a wholly-owned unit of the management company of RDIF to manufacture and supply Sputnik V, Sputnik Light vaccine against COVID-19, Wockhardt said in an exchange filing.

On receiving the necessary approvals and upon successful technology transfer from Human Vaccine LLC, the company will manufacture and supply to Enso up to 620 million doses of the Sputnik V and the Sputnik Light vaccines, it added.

"The term of the agreement is up to June 2023 for the contract manufacturing of up to 620 million doses of Sputnik V and Sputnik Light,” Wockhardt noted.